A Cleary Gottlieb representa muitas das maiores empresas farmacêuticas e de biotecnologia do mundo em importantes transações societárias assim como em questões de direito concorrencial, regulaçao, arbitragem e litígio. Assessoramos também instituições financeiras que auxiliam essas mesmas companhias em financiamentos dentro do mercado de capitais. Com a integração de nossos 12 escritórios internacionais, nossos advogados trabalham com rigor cruzando fronteiras e mantendo com êxito requerimentos de regulamentaçao multi-jurisdicional, possibilitando assim, fusões e aquisições, joint ventures e outras transações societárias.

As nossas principais áreas de atuação incluem:

• Regular EC law counsel to Merck & Co. on a cutting-edge issues, including in precedent-setting European Court of Justice win regarding the interpretation of the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights and in antitrust challenges by generic companies.
  
  
• Antitrust counsel to GlaxoSmithKline in connection with numerous transactions, including its recent $15 billion bid to acquire Pfizer’s consumer health care business.
  
  
• Counsel to Boehringer Ingelheim in precedent-setting European Court of Justice win regarding the scope of trademark owners’ rights in relation to parallel importers that repackage pharmaceutical products.
  
  
• Regular counsel to Medtronic on a range of matters, including in its $3.9 billion Kyphon acquisition.
  
  
• Counsel to TPG, Blackstone, Goldman Sachs and KKR in $10.9 billion Biomet acquisition—one of the largest LBOs of all time.
  
  
• Antitrust counsel to Merck & Co. in its collaboration with GTx to advance research and development of selective androgen receptor modulators (SARM).
  
  
• Regular global counsel to 3M, including in the sale of its global pharmaceuticals business to three buyers.
  
  
• Counsel to GlaxoSmithKline in many litigation matters, including a class action litigation in U.S. federal court relating to allegations of patent misuse in connection with Augmentin, GSK’s drugs for treating HIV/AIDS; a U.S. class action challenging GSK’s efforts to restrict illegal export and price-fixing of its products; the simultaneous resolution of a number of pending actions related to Wellbutrin XL; as well as on antitrust issues arising from the settlement of a patent litigation involving Paxil.
  
  
• Counsel to GlaxoSmithKline and its U.S. subsidiary SmithKline Beecham in the $1.65 billion acquisition of Reliant Pharmaceuticals, as well as to GSK in its acquisitions of Domantis Limited, Praecis Pharmaceuticals, CNS, ID Biomedical Corporation and Corixa.
  
  
• Counsel to Lundbeck in connection with the distribution of pharmaceutical products in Europe.